| Date | Time | Source | Headline | Symbol | Company |
| 05/02/2024 | 8:00AM | GlobeNewswire Inc. | Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows | NASDAQ:AKYA | Akoya BioSciences Inc |
| 04/22/2024 | 4:05PM | GlobeNewswire Inc. | Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024 | NASDAQ:AKYA | Akoya BioSciences Inc |
| 04/05/2024 | 8:00AM | GlobeNewswire Inc. | Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/04/2024 | 5:18PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/04/2024 | 4:05PM | GlobeNewswire Inc. | Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/04/2024 | 6:01AM | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/01/2024 | 9:58PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/01/2024 | 9:58PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/01/2024 | 9:53PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/01/2024 | 9:53PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/01/2024 | 9:52PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/01/2024 | 9:52PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 03/01/2024 | 9:21PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 02/12/2024 | 9:11AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:AKYA | Akoya BioSciences Inc |
| 02/08/2024 | 4:05PM | GlobeNewswire Inc. | Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference | NASDAQ:AKYA | Akoya BioSciences Inc |
| 01/18/2024 | 8:00AM | GlobeNewswire Inc. | Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases | NASDAQ:AKYA | Akoya BioSciences Inc |
| 01/10/2024 | 4:02PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AKYA | Akoya BioSciences Inc |
| 01/10/2024 | 8:00AM | GlobeNewswire Inc. | Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board | NASDAQ:AKYA | Akoya BioSciences Inc |
| 01/08/2024 | 3:57PM | Dow Jones News | Akoya Biosciences Shares Jump on 2024 Outlook, Thermo Fisher Deal | NASDAQ:AKYA | Akoya BioSciences Inc |
| 01/08/2024 | 6:02AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AKYA | Akoya BioSciences Inc |
| 01/07/2024 | 8:00AM | GlobeNewswire Inc. | Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform | NASDAQ:AKYA | Akoya BioSciences Inc |
| 01/07/2024 | 8:00AM | GlobeNewswire Inc. | Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow | NASDAQ:AKYA | Akoya BioSciences Inc |
| 01/07/2024 | 8:00AM | GlobeNewswire Inc. | Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook | NASDAQ:AKYA | Akoya BioSciences Inc |
| 01/03/2024 | 8:50AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:AKYA | Akoya BioSciences Inc |
| 12/20/2023 | 7:16PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 12/20/2023 | 8:05AM | GlobeNewswire Inc. | Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:AKYA | Akoya BioSciences Inc |
| 12/19/2023 | 4:23PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 12/14/2023 | 4:24PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 12/12/2023 | 6:33PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:AKYA | Akoya BioSciences Inc |
| 11/27/2023 | 5:40PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKYA | Akoya BioSciences Inc |